Polaryx Therapeutics

Polaryx Therapeutics is a late-stage clinical biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, which are rare inherited metabolic diseases. The company aims to address these conditions through innovative drug candidates that include new chemical entities and rep... urposed drugs, with a pipeline targeting diseases such as Krabbe, Sandhoff, and Niemann Pick types A and B. Polaryx is committed to creating formulations that ensure high compliance, particularly in pediatric populations, utilizing intranasal and oral delivery methods. Established in 2014, Polaryx Therapeutics operates under experienced leadership dedicated to the safe and effective commercialization of its therapies.Read More